1-2 of 2
Célia Salanoubat
Close
Sort by
Journal Articles

Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program.

Raphael Itzykson, Sylvain Thépot, Bruno Quesnel, Odile Beyne-Rauzy, MD, PhD, Francois Dreyfus, MD, PhD, Norbert Vey, MD, Pascal Turlure, MD, Laurence Legros, Caroline Dartigeas, Jacques Delaunay, MD, Stephane de Botton, MD, PhD, Emmanuel Raffoux, MD, Anne-Laure Taksin, MD, Aspasia Stamatoullas, Anne Marfaing Koka, Eric Wattel, MD, PhD, Sorin Visanica, MD, Célia Salanoubat, Pierre Morel, MD, Pascale Cony Makhoul, Stéphane Cheze, Laurence Sanhes, Isabelle Plantier, Gerard Tertian, Mehdi Dahoun, Agnes Guerci, MD, PhD, Claude Gardin, Lionel Ades, MD, Pierre Fenaux
Journal: Blood
Blood (2009) 114 (22): 3820.
https://doi.org/10.1182/blood.V114.22.3820.3820
Published: 2009
Journal Articles

Dasatinib (Sprycel®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Positive ALL: Results of the First 22 Patients Included in the EWALL-Ph-01 Trial (on Behalf of the European Working Group on Adult ALL (EWALL))

Philippe Rousselot, Jean-Michel Cayuela, Christian Recher, Thibaut Leguay, Célia Salanoubat, Francis Witz, Magda Alexis, Maud Janvier, Mathilde Hunault, Philippe Agape, Christian Berthou, Eric Jourdan, José Fernandes, Laurent Sutton, Anne Banos, Oumedaly Reman, Bruno Lioure, MD, Nicola Gökbuget, Dieter Hoelzer, MD, PhD, André Delannoy, Renato Bassan, Jose-Maria Ribera, Sebastian Giebel, Sandrine Hayette, Oliver Ottmann, Hervé Dombret
Journal: Blood
Blood (2008) 112 (11): 2920.
https://doi.org/10.1182/blood.V112.11.2920.2920
Published: 2008